AdipoLABs Announces REMISSION 1℃ Clinical Results at 6th IVRA

Inviting domestic and international speakers to introduce cancer improvement cases… CEO Han Sung-ho explains the operating principle of high-frequency cancer treatment device

 [Medical Newspaper/Daily Newspaper=Reporter Oh In-gyu] The greatest hurdle to the dream of extending human life is ‘cancer’. Mankind has been painstakingly analyzing cancer treatment for the past 100 years. As a result, widely practiced cancer treatment methods in the medical industry have been surgical treatment, radiation treatment, and chemotherapy. However, these treatments have the definite disadvantage of causing serious side effects to the human body from the start of treatment until complete recovery or death.

Recently, the medical community is paying close attention to immunotherapy as a new cancer treatment method, and interest in high-frequency hyperthermia therapy, which enhances the body's internal temperature to activate immunity and eradicate cancer cells, is also growing. Many papers have been published to clearly indicate that if the body temperature is somehow increased in the deep part of our body, it will have a double effect of necrotizing cancer cells that are vulnerable to heat while increasing immunity dramatically.

However, safely raising the deep body temperature to 42℃ or higher was a grave challenge, and the company, AdipoLABs has stepped up to come up with its REMISSION 1℃, a high-frequency hyperthermia cancer treatment device that was approved as a Class 3 medical device for cancer treatment by the Korean Ministry of Food and Drug Safety in 2015. The equipment is being used as a medical device that raises the deep body temperature to 42℃ or higher in countries of Korea, China, Malaysia, India, and more.

AdipoLABs (CEO Han Sung-ho) has announced that the device had produced numerous clinical results for the past 9 years, and that the various revered doctors from around the world will present these superb cancer treatment results at the Maria Hall of Seoul St. Mary's Hospital when the 6th IVRA (International Virus Research Alliance) event will be held on June 9.

This event will invite approximately 200 overseas cancer treatment specialists, 300 domestic medical professionals, and cancer patients and their families to hold an academic seminar. In particular, overseas participants include Dr. Hassan Basri Jahubar Sathik (Chief Director, Cyberjaya University, Malaysia), Dr. Damodara Kumaran (Head of Radiation Clinical Oncology, Krishna Cancer Institute, Cuddalore and Puducherry Cancer Trust Hospital, India), and Dr. Nagraj G. Huilgol (Chief Radiation Oncologist, Vallabhbhai Nanavati Hospital, India).

Also speaking will be Dr Kenny Yong Yean Sim (Director, Well Again HealthCare Center, Malaysia), Dr. Juliana Samuel (Director, Klinik Famili Hospital, Sabah, Malaysia), and Dr. Alsharif Ibrahim Ahmed M (MD, General Manager: Bedayah Specialist Center for Physiotherapy, Saudi Arabia).

Domestic speakers include cancer treatment authority Dr. Kim Eui-shin (life professor at MD Anderson University in Texas, USA, and professor at Seoul National University), Professor Jang Hong-seok and Kang Young-nam of Seoul St. Mary’s Hospital (Department of Radiation Oncology, Catholic University of Korea), Professor Choi Il-bong of the Korean Society of Thermology (Jeju National University Distinguished Professor), Director Yoo Seung-mo of Yesan Myongji Hospital in South Chungcheong Province and head of IVRA, Director Kim Seon-man of Amirang Hospital in Suwon specializing in cancer treatment, Director Shin Hyeong-jin of EM365 Hospital in Hwaseong, Director Yang Jae-ho of Jongno Chihyu Oriental Hospital, Director Ryu Jeong-man of Cheongju Nabisol Oriental Hospital in North Chungcheong Province, and Director Lee Chan-yong of Seoul Oncare.

By announcing vivid clinical results of cancer treatment, the group will deliver hope to cancer patients. In addition, AdipoLABs’ CEO Han Sung-ho will come forward to explain how the company’s high-frequency cancer treatment device works and how it provides painless treatment.

A company official explained, “This conference, where domestic and international cancer specialists give lectures on diverse cases of improvement under the theme of ‘This is how we conquer cancer,’ is not just coming from academic content, but also covers various clinical cases tailored to the general public, so we can say it can be useful to a large number of cancer patients and their families attending this time.”

This conference can be depicted as an international cancer treatment of hope where domestic and international experts present and discuss cases of eclectic cancer treatments centered on hyperthermia. In this academic seminar, we can expect the role of hyperthermia among various treatment methods for modern malignant tumors, the effectiveness and clinical experience of high-frequency hyperthermia in cancer treatment, the use of hyperthermia in cancer treatment, and the activation of immunity through hyperthermia to be well demonstrated.

Source: AdipoLABs, 6th IVRA, REMISSION 1℃ clinical results announced < Medical Devices/IT < Article - Medical Newspaper (bosa.co.kr)